Lakefront Biotherapeutics NV GLPGF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 292.58M | 299.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 292.58M | 299.27M |
| Cost of Revenue | -- | -- | -- | 534.33M | 477.44M |
| Gross Profit | -- | -- | -- | -241.74M | -178.17M |
| SG&A Expenses | -- | -- | -- | 152.61M | 136.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -41.57M | -42.40M |
| Total Operating Expenses | -- | -- | -- | 645.36M | 571.92M |
| Operating Income | -- | -- | -- | -352.78M | -272.65M |
| Income Before Tax | -- | -- | -- | -316.07M | -316.80M |
| Income Tax Expenses | -- | -- | -- | -2.55M | -2.61M |
| Earnings from Continuing Operations | -- | -- | -- | -313.52 | -314.20 |
| Earnings from Discontinued Operations | -- | -- | -- | 1.97M | 4.28M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -311.54M | -309.91M |
| EBIT | -- | -- | -- | -352.78M | -272.65M |
| EBITDA | -- | -- | -- | -299.98M | -227.63M |
| EPS Basic | -- | -- | -- | -4.73 | -4.70 |
| Normalized Basic EPS | -- | -- | -- | -2.40 | -1.35 |
| EPS Diluted | -- | -- | -- | -4.73 | -4.71 |
| Normalized Diluted EPS | -- | -- | -- | -2.40 | -1.35 |
| Average Basic Shares Outstanding | -- | -- | -- | 263.63M | 263.59M |
| Average Diluted Shares Outstanding | -- | -- | -- | 263.68M | 263.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |